Pharmaceutical giant Sanofi has announced plans to invest at least $20bn into its US manufacturing capacity during the next five years.
The investment will also focus on research and development, with the company planning to increase its spending within the region to fast-track its current development initiatives.
This follows a stream of investments placed on US manufacturing, with big-hitters such as Johnson & Johnson, Novartis, Eli Lilly, Roche and AstraZeneca placing their bets on the market following the Trump Administration's tariff threats.
With this investment, Sanofi will substantially increase spending in its US R&D operations, while expanding its manufacturing capacity.
This includes through direct investments in current Sanofi-owned sites, as well as through partnerships with domestic manufacturers.
Through this investment, Sanofi hopes to ensure the US' supply chain resilience, while better catering to the ever-present need for pharmaceuticals within the region.
"Sanofi's 13,000 US-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas," noted Sanofi's CEO, Paul Hudson.
"Our expected investments in the US will be substantial and will help ensure the production of key medicines in the US."
According to the company, its investment decisions will be adjusted as the market evolves.
Sanof's planned investments are expected to create a significant number of high-paying jobs in multiple states in the coming years, boosting the US economy and ensuring its healthcare autonomy.